Why Corcept Therapeutics Shares Climbed 10.8% Today
After news broke that shares will soon be included in the S&P Small Cap 600 index, Corcept Therapeutics' (NASDAQ: CORT) stock price jumped by 10.8% today.
The addition to the S&P 600 Small Cap Index means funds that track the index have to buy shares, but that doesn't necessarily make this company's stock a buy for the average investor. To determine that, investors need to better understand how the company's making its money now and how it plans to drive growth in the future. Currently, Corcept Therapeutics markets one drug: Korlym, a cortisol-targeting drug that treats endogenous Cushing's disease.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Corcept Therapeutics Inc. Aktie
Die Community zeigt eindeutige Unterstützung für Corcept Therapeutics Inc. mit mehreren Buy-Einschätzungen und keinen Sell-Einschätzungen.
Ein positives, aber moderates Potenzial für Corcept Therapeutics Inc. mit einem Kursziel von 36 € im Vergleich zu 30.82 €.